Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Acquisition Strategy Heats Up With Kosan Buy

Executive Summary

Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences

You may also be interested in...



Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval

Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012

Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval

Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012

Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom

Analysts question whether firm’s “string of pearls” growth strategy can offset patent hit.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel